Amgen (AMGN) Equity Income (2020 - 2025)

Amgen (AMGN) has reported Equity Income for 6 consecutive years, with $10.0 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Equity Income rose 135.71% year-over-year to $10.0 million; the TTM figure through Sep 2025 stood at -$20.0 million (down 17.65% YoY), while the FY2024 annual figure was $10.0 million, up 190.91% from the prior year.
• Equity Income came in at $10.0 million for Q3 2025 at Amgen, up from -$18.0 million in the prior quarter.
• The five-year high for Equity Income was $97.0 million in Q4 2021, with the low at -$305.0 million in Q1 2022.
• Average Equity Income over 5 years is -$31.0 million, with a median of -$11.0 million recorded in 2025.
• Across the five-year window, Equity Income slumped 671.43% in 2022 and jumped 142.86% in 2024, its largest moves.
• Year by year, Equity Income stood at $97.0 million in 2021, then plunged by 283.51% to -$178.0 million in 2022, then surged by 84.27% to -$28.0 million in 2023, then soared by 96.43% to -$1.0 million in 2024, then jumped by 1100.0% to $10.0 million in 2025.
• According to Business Quant data, Equity Income over the past three periods registered $10.0 million, -$18.0 million, and -$11.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.